Medical Affairs: Closing the gap between access and adoption
Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.
Improving lives through clinical trials
Marjorie Lazarre has seen the life-changing outcomes of T1D research and is confident clinical trials are the path to cures.
A behind-the-scenes look at DIAGNODE-3: Phase 3 clinical trials of Diamyd® for T1D
DIAGNODE-3 is a phase 3 clinical trial of the disease-modifying therapy Diamyd® that aims to preserve insulin-producing beta cells.
Cell therapy first: transplanted islets working without immunosuppressives
The recipient of gene-edited islets to evade the immune system is making insulin without the use of immunusuppresives.
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D. This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D. Here are the […]
Clinical Trials in Action: Aiedan’s Story
Meet Aiedan, a participant in the T1D RELAY clinical trial that aims to preserve insulin production in those newly diagnosed with type 1 diabetes.
Putting the Foxes in Charge of the Henhouse: The Dramatic Race to Develop an Artificial Pancreas
The true story of how artificial pancreas systems moved from an idea to a therapy, improving the lives of millions with type 1 diabetes.
Meet Alecia Wesner, a hero for T1D clinical trials
Since 2014, Alecia Wesner has participated in numerous T1D clinical trials, many of which were early artificial pancreas system trials.
Vertex launches pivotal trial for stem-cell derived islet therapy
Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]
